Press Releases

H3 Biomedicine Appoints Lihua Yu, Ph.D., to Chief Data Sciences Officer

Cambridge, Mass., May 01, 2017 — H3 Biomedicine Inc., a clinical stage biopharmaceutical company specializing in the discovery and development of precision medicines for oncology and a member of Eisai’s global Oncology Business Group, announced today that Lihua Yu, Ph.D., has been promoted to Chief Data Sciences Officer (CDSO). Dr. Yu previously served as H3 Biomedicine’s Vice President, Data Science and Information Technology.

“Lihua’s appointment to Chief Data Sciences Officer fills a critical element in H3’s step towards building a comprehensive oncology pipeline and supporting the next generation of novel cancer drugs,” said Markus Warmuth, M.D., President and CEO of H3 Biomedicine. “Lihua’s proven commitment and expertise in establishing and expanding the use of data technology at H3 helped fuel the company’s growth through the integration of data science and cancer genomics, which has rapidly generated a superior informatics analysis engine.”

In her new role, Dr. Yu will oversee H3 Biomedicine’s computational biology and data mining activities, including the management of the company’s cancer genomics and pharmacogenomics data. Additionally, she will supervise the identification and integration of all data analysis capabilities for discovery, preclinical and clinical data. Dr. Yu will also lead the Discovery Informatics team in developing genomics data management, integration, and exploration solutions to enable data mining and utilization across the company.

Dr. Yu has over 17 years of experience in computational biology and bioinformatics, as well as deep knowledge in the area of cancer genomics and predictive biomarkers. Before joining H3 Biomedicine in 2011, Dr. Yu spent 12 years with AstraZeneca’s research and development unit, helping to build and deliver the multinational pharmaceutical company’s oncology bioinformatics capabilities. During her time there, she provided bioinformatics support to key areas of oncology drug discovery programs, including target identification and patient selection initiatives.

“I am honored to serve as CDSO at such an exciting and pivotal time in the company’s trajectory. H3 continues to leverage distinct insights from cancer genomic data and patient information to advance our projects,” said Dr. Yu. “The strength of our science and success of our efforts to date are a direct result of H3’s understanding of and ability to explore genomic data through a BioIT eco-system, which remains an integral part of our genomics driven cancer drug discovery and development programs.”

About H3 Biomedicine Inc.

H3 Biomedicine is a Cambridge, Massachusetts-based biopharmaceutical company specializing in the discovery and development of precision oncology treatments, which was established as a subsidiary of Eisai's U.S. pharmaceutical operation Eisai Inc. Leveraging this collaboration with Eisai Co., Ltd., who through this partnership provides essential research funding and access to the capabilities and resources of this global pharmaceutical company, H3 Biomedicine combines long-term vision with operational independence. Using modern synthetic chemistry, chemical biology, and human genetics, H3 Biomedicine seeks to bring the next generation of cancer treatments to market with the goal of improving the lives of patients. For more information, please visit www.h3biomedicine.com.